


# Figure 4-supplement 1

**A**


Validated Rabgap1l and Gpr52 transcripts in human and mouse

red: GAP transcripts; green: non-GAP transcripts; blue: Gpr52


*Homo sapiens* (human)



*Mus musculus* (house mouse)




**B** qPCR validation of Rabgap1l siRNAs



**C**

Increase of Htt levels by Rabgap1l siRNAs



**Figure 4-supplement 1.** *Rabgap1l* genomic information and siRNA validation

**(A)** Genomic loci of Rabgap1l and Gpr52.

**(B)** qPCR quantification of the Rabgap1l mRNA level of STHdh cells transfected with Rabgap1l siRNAs or the non-targeting control siRNA (Neg). 50~80% knock-down could be achieved by siRNA transfection in these cells.

**(C)** Western-blot (*left*) and HTRF (*right*) experiments showing that Rabgap1l knock-down by siRNA increases the Htt level in the STHdh cells. Hdh5 and B01 are Htt siRNAs used as positive controls. For HTRF, the 2B7/2166 antibody pair was used. Data are plotted as mean and s.e.m, n = 16 for non-targeting siRNA control (Neg) samples, and n = 12 for Rabgap1l siRNA transfected samples. “\*\*\*”: P < 0.001 by the two-tailed Mann–Whitney U-test.